BR0308634A - Uso de um adenovìrus, e, composição - Google Patents

Uso de um adenovìrus, e, composição

Info

Publication number
BR0308634A
BR0308634A BR0308634-8A BR0308634A BR0308634A BR 0308634 A BR0308634 A BR 0308634A BR 0308634 A BR0308634 A BR 0308634A BR 0308634 A BR0308634 A BR 0308634A
Authority
BR
Brazil
Prior art keywords
adenovirus
composition
rnas
vai
mutations
Prior art date
Application number
BR0308634-8A
Other languages
English (en)
Inventor
Ramon Alemany Bonastre
Manel Maria Cascallo Piqueras
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of BR0308634A publication Critical patent/BR0308634A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C12N2710/10364—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"USO DE UM ADENOVìRUS, E, COMPOSIçãO". A presente invenção diz respeito à utilização de um adenovírus para o tratamento do câncer. A invenção é caracterizada pelo fato de que o adenovírus é defeituoso em seus RNAs vírus-associados (VA), referidos adenovírus tendo uma mutação na seq³ência do gene VAI ou VAII, ou de ambos. Referido adenovírus também pode ter uma mutação nas seq³ências que controlam a expressão dos RNAs VA.
BR0308634-8A 2002-03-26 2003-03-25 Uso de um adenovìrus, e, composição BR0308634A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200200716 2002-03-26
PCT/ES2003/000140 WO2003080083A1 (es) 2002-03-26 2003-03-25 Uso de adenovirus mutados en los genes va para el tratamiento del cancer

Publications (1)

Publication Number Publication Date
BR0308634A true BR0308634A (pt) 2005-02-15

Family

ID=27772025

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308634-8A BR0308634A (pt) 2002-03-26 2003-03-25 Uso de um adenovìrus, e, composição

Country Status (14)

Country Link
US (3) US7344711B2 (pt)
EP (2) EP1605053A1 (pt)
JP (2) JP2005526099A (pt)
AT (1) ATE309812T1 (pt)
AU (1) AU2003226835B2 (pt)
BR (1) BR0308634A (pt)
CA (1) CA2478616C (pt)
DE (1) DE60302350T2 (pt)
DK (1) DK1498129T3 (pt)
ES (1) ES2248764T3 (pt)
HK (1) HK1071060A1 (pt)
IL (2) IL163745A0 (pt)
MX (1) MXPA04009204A (pt)
WO (1) WO2003080083A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1605053A1 (en) * 2002-03-26 2005-12-14 Oncolytics Biotech Inc. Use of adenoviruses mutated in the VA genes for cancer treatment
WO2007099401A2 (en) 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US20070292396A1 (en) * 2006-03-02 2007-12-20 Juan Fueyo Combination therapy with oncolytic adenovirus
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
ES2355882B1 (es) 2009-03-24 2012-02-13 INSTITUT CATALÀ D`ONCOLOGIA (Titular al 50%) Combinación de adenovirus oncolítico y un bloqueador de canal de calcio y su uso para el tratamiento del cáncer.
JPWO2012121071A1 (ja) * 2011-03-04 2014-07-17 国立大学法人大阪大学 ＶＡ−ＲＮＡｓが発現しないアデノウイルスベクター
EP2971008B1 (en) 2013-03-14 2018-07-25 Salk Institute for Biological Studies Oncolytic adenovirus compositions
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
US20210340279A1 (en) 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
KR20220038485A (ko) 2019-08-05 2022-03-28 메조블라스트 인터내셔널 에스에이알엘 바이러스 벡터를 포함하는 세포 조성물 및 치료 방법
US20230293590A1 (en) 2020-08-10 2023-09-21 Mesoblast International Sárl Cellular compositions and methods of treatment
WO2024081736A2 (en) 2022-10-11 2024-04-18 Yale University Compositions and methods of using cell-penetrating antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648301B2 (ja) * 1983-12-27 1997-08-27 ジエネテイツクス・インスチチユ−ト・インコ−ポレ−テツド 真核細胞の形質転換のための補助ｄｎａを含むベクター
US5079159A (en) * 1983-12-27 1992-01-07 Genetics Institute, Inc. Method for making tissue plasminogen activator
US5002874A (en) * 1987-09-17 1991-03-26 Genetics Institute, Inc. Genetically engineered eucaryotic host cells capable of expressing modified forms of eIF-2α
US5985846A (en) * 1995-06-07 1999-11-16 Baylor College Of Medicine Gene therapy for muscular dystrophy
US6254862B1 (en) * 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US6403370B1 (en) * 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
US5981225A (en) * 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
WO1999057296A1 (en) * 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
CA2720361A1 (en) * 1999-11-12 2001-05-25 Oncolytics Biotech, Inc. Viruses for the treatment of cellular proliferative disorders
US20040132675A1 (en) * 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
WO2003022311A1 (en) * 2001-09-13 2003-03-20 Genvec, Inc. Adenoviral vector and related system and methods of making and use
EP1605053A1 (en) * 2002-03-26 2005-12-14 Oncolytics Biotech Inc. Use of adenoviruses mutated in the VA genes for cancer treatment
EP1567198A4 (en) * 2002-12-02 2006-05-31 Genvec Inc MATERIALS AND METHOD FOR THE TREATMENT OF EYE DISEASES

Also Published As

Publication number Publication date
DE60302350D1 (de) 2005-12-22
MXPA04009204A (es) 2004-11-26
US20080089864A1 (en) 2008-04-17
CA2478616C (en) 2012-05-29
DE60302350T2 (de) 2006-08-03
JP2010184940A (ja) 2010-08-26
AU2003226835A1 (en) 2003-10-08
US20060233753A1 (en) 2006-10-19
US20110053249A1 (en) 2011-03-03
JP2005526099A (ja) 2005-09-02
IL163745A0 (en) 2005-12-18
WO2003080083A1 (es) 2003-10-02
CA2478616A1 (en) 2003-10-02
AU2003226835B2 (en) 2006-11-09
EP1498129A1 (en) 2005-01-19
IL163745A (en) 2010-02-17
EP1605053A1 (en) 2005-12-14
HK1071060A1 (en) 2005-07-08
US20090202489A2 (en) 2009-08-13
EP1498129B1 (en) 2005-11-16
ATE309812T1 (de) 2005-12-15
DK1498129T3 (da) 2006-04-03
US7344711B2 (en) 2008-03-18
ES2248764T3 (es) 2006-03-16

Similar Documents

Publication Publication Date Title
HK1071060A1 (en) Use of adenoviruses mutated in the va genes for cancer treatment
WO2008013589A3 (en) Treatment of ras-expressing tumors
IL190796A0 (en) Compositions and their uses for gene therapy of bone conditions
WO2006020768A3 (en) Chemically modified oligonucleotides
GEP20125594B (en) Sclerostin binding agents
MX2009004510A (es) Oligorribonucleotidos y sus usos.
WO2006074351A3 (en) Reversible nucleotide terminators and uses thereof
NO20062420L (no) Anvendelse av IAP-oligomer og et kjemoterapeutisk middel for behandling av proliferative sykdommer
ATE554114T1 (de) Copolymer mit zwitterionischen einheiten und anderen einheiten, das copolymer umfassende zusammensetzung und verwendung
ATE508188T1 (de) Oligonukleotid-zusammensetzungen mit verbesserter wirksamkeit
WO2004066941A3 (en) Expression profiles for colon cancer and methods of use
AU2002360820A8 (en) Compositions for dna mediated gene silencing
ATE516052T1 (de) Zusammensetzungen für knochenzemente enthaltend eine nichtpolymerisierbare organoiodverbindung
WO2004096842A3 (en) Sars virus nucleotide and amino acid sequences and uses thereof
TW200716088A (en) Formulations and methods for treating amyloidosis
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
MX2008000059A (es) Marcadores de fibrosis.
WO2006107946A3 (en) Bone cement compositions and the like comprising an rnaiii-inhibiting peptide
WO2005094761A8 (en) Hair treatment compositions comprising a disaccharide, a di-acid and a source of ammonium ions
AU2003294785A1 (en) Hair treatment compositions
BRPI0410467A (pt) composições e métodos para tratamento de sìndrome respiratória aguda severa (sars)
TW200605885A (en) Multicyclic lonidamine analogs
NO20022149D0 (no) Ikke-viralt genleveringssystem
WO2005010149A3 (en) Subgroup b adenoviral vectors for treating disease
WO2004110365A3 (en) Liver related disease compositions and methods

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A(S) 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011.